This article deals with the changes to the dual labelling period as of April 30, 2023, by TGA Australia. The labels, Product Information (PI), and Consumer Medicines Information (CMI) papers are now requesting dual labelling for multiple ingredient names used in medications. It also indicates that labels will have both the old and new ingredient names. This was done in order to familiarize people with the new names. Medicine manufacturers have three years to alter their labels to reflect solely the new name for these substances. More details on the transition can be obtained on: Medicine Ingredient Names
For Health Care Workers
Medicines with labels that only contain the sole ingredient name will begin to appear on store shelves when the dual labelling periods expire. For instance, medicines containing “lidocaine (lignocaine)” will begin being identified as containing ‘lidocaine’ on April 30, 2023. More details can be found on: Understand ingredient names on medicine labels as they transition to show new names only
For Consumers
If a consumer sees an ingredient name, he/she doesn’t understand, they are urged to speak to a healthcare professional
Connect us
Get the latest and most updated medical news from across the world (US FDA TGA Australia etc) by subscribing to the Morulaa website. Please get in touch with us if you need help registering medical devices in India or other Southeast Asian nations.
Source: tga.gov.au
